Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 801–900 of 10,906
Shavit, R., Segal, R. M., Kidon, M. I., Offengenden, I., Yahia, S. H., Machnes‐Maayan, D., Lifshitz, Y., Niznik, S., Frizinsky, S., Deutch, M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22255 · Cited by 94
Lipid nanoparticles: Composition, formulation, and application
Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 126
“33 In addition to these FDA-approved benchmark ionizable lipids, more additional ionizable lipids have entered clinical trials or reported in preclinical studies.”
Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
Chavda, V. P., Hossain, M. M. M., Beladiya, J., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1030020 · Cited by 100
Amodio, D., Ruggiero, A., Sgrulletti, M., Pighi, C., Cotugno, N., Medri, C., Rocchi, F., Colagrossi, L., Russo, C., Zaffina, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727850 · Cited by 107
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 111
Khan, N. H., & Mahmud, N. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.044 · Cited by 96
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 107
(2021) · doi:10.1101/2021.05.04.442663 · Cited by 259
Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
Muri, J., Cecchinato, V., Cavalli, A., Shanbhag, A. A., Matkovic, M., Biggiogero, M., Maida, P. A., Moritz, J., Toscano, C., Ghovehoud, E., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01445-w · Cited by 104
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 120
Watanabe, A., Kani, R., Iwagami, M., Takagi, H., Yasuhara, J., & Kuno, T. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.6243 · Cited by 106
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 107
COVID-19 Vaccine Acceptance among College Students: A Theory-Based Analysis
Sharma, M., Davis, R. E., & Wilkerson, A. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094617 · Cited by 92
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
“After the recent success of SARS-CoV-2 vaccines, lipid nanoparticles have become widely known vectors for delivering genetic material [48,49].”
BackgroundAllergy to COVID-19 vaccines: A current update
Cabanillas, B., & Novak, N. (2021) · Allergology International · doi:10.1016/j.alit.2021.04.003 · Cited by 99
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity
Delmonte, O. M., Bergerson, J., Burbelo, P. D., Durkee-Shock, J. R., Dobbs, K., Bosticardo, M., Keller, M. D., McDermott, D. H., Rao, V. K., Dimitrova, D., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.016 · Cited by 94
Britton, A., Fleming-Dutra, K. E., Shang, N., Smith, Z., Dorji, T., Derado, G., Accorsi, E. K., Ajani, U. A., Miller, J., Schrag, S. J., et al. (2022) · JAMA · doi:10.1001/jama.2022.2068 · Cited by 84
Self-citationImmune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01262-1 · Cited by 106
Self-citationAdverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease
Botwin, G. J., Li, D., Figueiredo, J. C., Cheng, S. C., Braun, J. G., McGovern, D. P. B., & Melmed, G. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001342 · Cited by 88
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 101
Waggoner, L. E., Miyasaki, K. F., & Kwon, E. J. (2023) · Biomaterials Science · doi:10.1039/d2bm01846b · Cited by 112
The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations
Stafford, I. A., Parchem, J. G., & Sibai, B. M. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.01.022 · Cited by 89
Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
Zhang, L., Dutta, S., Xiong, S., Chan, M. C., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M. O., Cooper, L. M., Rong, L., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00965-6 · Cited by 89
Prevention of host-to-host transmission by SARS-CoV-2 vaccines
Mostaghimi, D., Valdez, C. N., Larson, H. T., Kalinich, C. C., & Iwasaki, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00472-2 · Cited by 108
COVID-19 vaccines: Considering sex differences in efficacy and safety
Jensen, A., Strømme, M., Moyassari, S., Chadha, A. S., Tartaglia, M. C., Szoeke, C. E. I., & Ferretti, M. T. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106700 · Cited by 96
Hồ, N. T., Hughes, S. G., Ta, V. T., Lan, P. T., Đỗ, Q., Nguyễn, T. V., Phạm, A. T. V., Đặng, M. T. N., Nguyễn, L. V., Trịnh, Q. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47905-1 · Cited by 103
Praet, J. T. V., Reynders, M., Bacquer, D. D., Viaene, L., Schoutteten, M., Caluwé, R., Doubel, P., Heylen, L., Bel, A. V. D., Vlem, B. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070908 · Cited by 90
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 99
Edmonds, C. E., Zuckerman, S. P., & Conant, E. F. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25604 · Cited by 90
De novo vasculitis after mRNA-1273 (Moderna) vaccination
Anderegg, M. A., Liu, M., Saganas, C., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.016 · Cited by 90
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmissionPreprint
Eyre, D., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K., Walker, A., & Peto, T. (2021) · medRxiv · doi:10.1101/2021.09.28.21264260 · Cited by 105
Hakroush, S., & Tampe, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762006 · Cited by 99
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S. W., Reynoso, L., Downey, G. P., Frankel, S. K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1919285 · Cited by 97
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
(2021) · doi:10.1016/j.vaccine.2021.11.001 · Cited by 101
Self-citationMaruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J. T., McAuliffe, J., Kanitkar, A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.001 · Cited by 88
Roghani, A. (2021) · JMIRx Med · doi:10.2196/29324 · Cited by 89
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. (2021) · mBio · doi:10.1128/mbio.01140-21 · Cited by 86
Naranbhai, V., Pernat, C. A., Gavralidis, A., Denis, K. S., Lam, E. C., Spring, L. M., Isakoff, S. J., Farmer, J. R., Zubiri, L., Hobbs, G. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01891 · Cited by 93
Nawaz, M., Heydarkhan‐Hagvall, S., Tangruksa, B., González‐King, H., Jing, Y., Maugeri, M., Kohl, F., Hultin, L., Reyahi, A., Camponeschi, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202206187 · Cited by 100
Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., et al. (2023) · Blood · doi:10.1182/blood.2022019333 · Cited by 97
Current approaches to HIV vaccine development: a narrative review
Kim, J., Vasan, S., Kim, J. H., & Ake, J. A. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25793 · Cited by 108
Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 89
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
Creytens, S., Pascha, M. N., Ballegeer, M., Saelens, X., & de Haan, C. A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786617 · Cited by 96
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper
Barbaud, A. M., Garvey, L. H., Arcolacı, A., Brockow, K., Mori, F., Mayorga, C., Bonadonna, P., Atanasković‐Marković, M., Moral, L., Zanoni, G., et al. (2022) · Allergy · doi:10.1111/all.15241 · Cited by 92
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
Kahn, R., Schrag, S. J., Verani, J. R., & Lipsitch, M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac015 · Cited by 76
Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
Nathan, A., Rossin, E. J., Kaseke, C., Park, R. J., Khatri, A., Koundakjian, D., Urbach, J. M., Singh, N. K., Bashirova, A., Tano-Menka, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.029 · Cited by 87
August, A., Shaw, C. A., Lee, H. R., Knightly, C., Kalidindia, S., Chu, L., Essink, B. J., Seger, W., Zaks, T. Z., Smolenov, I. V., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac206 · Cited by 97
Self-citationResponse to mRNA vaccination for COVID-19 among patients with multiple myeloma
Stampfer, S. D., Goldwater, M., Jew, S. K., Bujarski, S. E., Regidor, B. S. S., Daniely, D., Chen, H., Xu, N., Li, M., Green, T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01354-7 · Cited by 92
Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA
Hashiba, K., Sato, Y., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Shishido, T., Murakawa, M., Arimichi, O., & Harashima, H. (2022) · Small Science · doi:10.1002/smsc.202200071 · Cited by 113
US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
Lalani, H. S., Nagar, S., Sarpatwari, A., Barenie, R. E., Avorn, J., Rome, B. N., & Kesselheim, A. S. (2023) · BMJ · doi:10.1136/bmj-2022-073747 · Cited by 89
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
Carr, E. J., Wu, M., Harvey, R., Wall, E. C., Kelly, G. P., Hussain, S., Howell, M. T., Kassiotis, G., Swanton, C., Gandhi, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01854-7 · Cited by 93
Dalvie, N. C., Rodriguez‐Aponte, S. A., Hartwell, B. L., Tostanoski, L. H., Biedermann, A. M., Crowell, L. E., Kaur, K., Kumru, O. S., Carter, L. P., Yu, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106845118 · Cited by 91
Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine
Fowler, N., Martinez, N. R. M., Pallares, B. V., et al. (2021) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2021.101136 · Cited by 88
Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role
Samuel, S. M., Varghese, E., & Büsselberg, D. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.004 · Cited by 92
Omo‐Lamai, S., Wang, Y., Patel, M. N., Milosavljevic, A., Zuschlag, D. W., Poddar, S., Wu, J., Wang, L., Dong, F., Espy, C. L., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01974-5 · Cited by 200
“In addition to efficient delivery of RNA, the other reason for the widespread use of LNPs is their safety record, which is well illustrated by the COVID-19 vaccines 4,5 .”
Yang, Z., Han, Y., Ding, S., Shi, W., Zhou, T., Finzi, A., Kwong, P. D., Mothes, W., & Lu, M. (2022) · mBio · doi:10.1128/mbio.03227-21 · Cited by 79
Huang, Q., Zeng, J., & Yan, J. (2021) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.02.006 · Cited by 87
Risk of reinfection and disease after SARS‐CoV ‐2 primary infection: Meta‐analysis
Flacco, M. E., Martellucci, C. A., Baccolini, V., Vito, C. D., Renzi, E., Villari, P., & Manzoli, L. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13845 · Cited by 98
Teh, J. S. K., Coussement, J., Neoh, Z. C. F., Spelman, T. D., Lazarakis, S., Slavin, M. A., & Teh, B. W. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006333 · Cited by 94
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 95
Vaccines for COVID-19: Where do we stand in 2021?
Sharma, K., Koirala, A., Nicolopoulos, K., Chiu, C., Wood, N., & Britton, P. N. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.001 · Cited by 101
Diamanti, A. P., Aiello, A., Laganà, B., Agrati, C., Castilletti, C., Meschi, S., Farroni, C., Lapa, D., Fard, S. N., Cuzzi, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.740249 · Cited by 94
Fei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 104
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A. S., Jeon, A. B., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh1655 · Cited by 109
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis
Cheng, H., Peng, Z., Luo, W., Si, S., Mo, M., Zhou, H., Xin, X., Liu, H., & Yu, Y. (2021) · Vaccines · doi:10.3390/vaccines9060582 · Cited by 91
Self-citationCOVID ‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era
Taga, A., & Lauria, G. (2022) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12482 · Cited by 97
Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 96
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis
Ling, Y., Zhong, J., & Luo, J. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27203 · Cited by 89
Ammirati, E., Cavalotti, C., Milazzo, A., Pedrotti, P., Soriano, F., Schroeder, J. W., Morici, N., Giannattasio, C., Frigerio, M., Metra, M., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100774 · Cited by 86
RetractedFailures of quarantine systems for preventing COVID‐19 outbreaks in Australia and New Zealand
Grout, L. M., Katar, A., Ouakrim, D. A., Summers, J. A., Kvalsvig, A., Baker, M. G., Blakely, T. A., & Wilson, N. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51240 · Cited by 84
Pardi, N., Carreño, J. M., O’Dell, G., Tan, J., Bajusz, C., Muramatsu, H., Rijnink, W. F., Strohmeier, S., Loganathan, M., Bielak, D. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32149-8 · Cited by 91
Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
Hsieh, C., Rush, S. A., Palomo, C., Chou, C., Pickens, W., Más, V., & McLellan, J. S. (2022) · Nature Communications · doi:10.1038/s41467-022-28931-3 · Cited by 89
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 115
Golan, Y., Prahl, M. K., Cassidy, A. G., Gay, C., Wu, A. H. B., Jigmeddagva, U., Lin, C. Y., Gonzalez, V. J., Basilio, E., Chidboy, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777103 · Cited by 96
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 103
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
Liebers, N., Speer, C., Benning, L., Bruch, P., Kraemer, I., Meißner, J., Schnitzler, P., Kräusslich, H., Dreger, P., Müller‐Tidow, C., et al. (2021) · Blood · doi:10.1182/blood.2021013445 · Cited by 93
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 99
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination
de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Khan, S., Palma, A. M., Parker, D. M., Chau, A. H., Specimen Collection Group, Hosseinian, S., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00396-3 · Cited by 88
mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 110
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
Escalona-Rayo, O., Zeng, Y., Knol, R. A., Kock, T. J. F., Aschmann, D., Slütter, B., & Kros, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115065 · Cited by 98
Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review
Keshavarz, P., Yazdanpanah, F., Rafiee, F., & Mizandari, M. (2021) · Academic Radiology · doi:10.1016/j.acra.2021.04.007 · Cited by 83
de Carvalho, B. G., Ceccato, B. T., Michelon, M., Han, S. W., & de la Torre, L. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010141 · Cited by 103
Self-citationCabezas, C., Coma, E., Mora, N., Li, X., Martínez, M., Avilés, F. F., Fàbregas, M., Hermosilla, E., Jover, A., Contel, J. C., et al. (2021) · BMJ · doi:10.1136/bmj.n1868 · Cited by 97
Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
White, E. M., Yang, X., Blackman, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104849 · Cited by 85
Arregocés-Castillo, L., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón-Medrano, L., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00035-6 · Cited by 97
SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility
Morris, R. S. (2021) · F&S Reports · doi:10.1016/j.xfre.2021.05.010 · Cited by 85
Zelkoski, A. E., Lu, Z., Sukumar, G., Dalgard, C. L., Said, H., Alameh, M., Mitre, E. E. S., & Malloy, A. M. W. (2025) · npj Vaccines · doi:10.1038/s41541-025-01124-x · Cited by 132
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
Wu, K., Choi, A., Koch, M., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., Bennett, H., et al. (2021) · doi:10.1101/2021.05.05.21256716 · Cited by 84
Self-citationFernández‐Nieto, D., Hammerle, J., Fernández-Escribano, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17250 · Cited by 84
Sun, W., He, L., Zhang, H., Tian, X., Bai, Z., Sun, L., Yang, L., Jia, X., Bi, Y., Luo, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00750-w · Cited by 85
mRNA lipid nanoparticle phase transition
Trollmann, M. F. W., & Böckmann, R. A. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.08.037 · Cited by 96
Dufour, J., Marjot, T., Becchetti, C., & Tilg, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326792 · Cited by 94
Bruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Takhar, H. S., Tubert, J. E., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100134 · Cited by 95
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Tang, P., Coyle, P., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 83
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
Ying, K., Zhu, Y., Wan, J., Zhan, C., Wang, Y., Xie, B., Xu, P., Pan, H., & Wang, H. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.06.013 · Cited by 103
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.